Ultra-low-dose doxepin (3 mg to 6 mg nightly, branded as Silenor) is FDA-approved and recommended by the American Academy of Sleep Medicine (AASM 2017) for sleep-maintenance insomnia. Because doxepin binds human-brain histamine H1 receptors with high affinity (Kd 0.24 nM, Ki < 1 nM) compared with alpha-1 adrenergic (Kd 24 nM) and muscarinic receptors (Kd 83 nM, Richelson & Nelson 1984), a 3 to 6 mg dose acts as a selective H1 blocker. In pooled polysomnography trials, 3 mg and 6 mg cut wake time after sleep onset (WASO) by 22.2 to 23.1 minutes and boost total sleep time by 26.1 to 32.3 minutes into the final hour of the night, keeping efficacy for 12 weeks (Krystal 2010) without rebound insomnia (Krystal 2011). The 2023 AGS Beers Criteria explicitly exempt doxepin at 6 mg/day or less while warning against doses above 6 mg/day and against first-generation antihistamines (hydroxyzine, diphenhydramine, and doxylamine).
TL;DR: Ultra-low-dose doxepin (3 mg or 6 mg at bedtime) is one of the few sleep medications that holds FDA approval and an AASM guideline recommendation for staying asleep:
- Dose changes which receptors wake up (3 to 6 mg vs. 10 to 300 mg): At 3 to 6 mg, doxepin blocks wake-promoting histamine H1 receptors (Kd 0.24 nM) while sparing muscarinic (Kd 83 nM) and alpha-1 (Kd 24 nM) receptors. At 10 mg to 150 mg, those off-target receptors engage. That turns doxepin into a classic tricyclic with dry mouth, constipation, and cognitive fog. The 2023 AGS Beers Criteria draw the safety line right at <= 6 mg/day.
- Built for 3:00 AM waking, not falling asleep (AASM 2017; Krystal 2010/2011): Across sleep-lab trials, doxepin 3 mg and 6 mg cut night waking (WASO) by 22 to 23 minutes and added 26 to 32 minutes of total sleep into the final hour of the night. It kept working at Week 12 (Night 85) with zero rebound insomnia when stopped.
- Safer and better tested than hydroxyzine, Benadryl, or Unisom: First-generation antihistamines lack chronic-insomnia PSG proof. They build daytime sedation tolerance within 4 days (diphenhydramine) or linger with a 20 to 29 hour half-life and QTc warnings (hydroxyzine).
- Take it on an empty stomach (>= 3 hours after dinner): Food raises doxepin absorption by 41% and delays peak blood levels by ~3 hours, which can cause morning grogginess.
Last month, a 68-year-old retired architect from Rittenhouse Square came into my Fishtown clinic exhausted. He fell asleep in ten minutes at 10:30 PM, woke up staring at the ceiling at 2:45 AM every night, and felt groggy until noon on the 25 mg generic doxepin capsule his prior doctor had called "low-dose for sleep." That 25 mg capsule is more than four times the FDA insomnia ceiling, pushing blood levels high enough to block muscarinic and alpha-1 receptors all morning. We ruled out sleep apnea with a home WatchPAT study and switched him to 3 mg of doxepin oral liquid taken three hours after dinner alongside CBT-I sleep consolidation. Within one week, his middle-of-the-night waking shrank from 75 minutes to under 15 minutes and his morning fog cleared.
Why are 3 to 6 mg and 75 to 300 mg of doxepin two different drugs?
Doxepin's intrinsic receptor binding does not change with dose, but higher blood levels recruit lower-affinity receptors. Because doxepin binds human-brain histamine H1 receptors (Kd 0.24 nM; FDA Ki < 1 nM) far more tightly than alpha-1 adrenergic (Kd 24 nM) or muscarinic receptors (Kd 83 nM), a 3 to 6 mg dose acts as a selective H1 blocker (Richelson & Nelson, JPET 1984).123
Doxepin was introduced in the 1960s as a tricyclic antidepressant at 75 to 300 mg/day. At those high doses, it blocks serotonin and norepinephrine transporters (SERT and NET) along with muscarinic and alpha-1 receptors. That broad blockade causes dry mouth, constipation, blurry vision, urinary retention, orthostatic dizziness, and heart conduction slowing.145
At 3 mg to 6 mg, blood levels stay high enough to occupy histamine H1 receptors while staying below the level needed for meaningful muscarinic or adrenergic blockade in most patients:236
| Receptor or Transporter Target | Human-Brain Binding Evidence | Role at Insomnia Doses (3 to 6 mg/day) | Role at Tricyclic Doses (75 to 300 mg/day, or >= 10 mg) |
|---|---|---|---|
| Histamine H1 Receptor | Kd 0.24 nM (Richelson 1984); Ki < 1 nM (FDA Label)12 | Primary active target: Quiets tuberomammillary wake signaling in the late night and early morning.23 | Saturated; heavy sedation.15 |
| Alpha-1 Adrenergic Receptor | Kd 24 nM (~100-fold lower affinity than H1)15 | Minimal clinical engagement at 3 to 6 mg in normal metabolizers.23 | Active blockade: Causes orthostatic blood-pressure drops, dizziness, and reflex tachycardia.15 |
| Muscarinic Acetylcholine (M1-M5) | Kd 83 nM non-subtype-specific (~345-fold lower than H1)17 | Anticholinergic side effects and memory complaints match placebo in 3 to 6 mg trials.289 | Strong anticholinergic load: Dry mouth, constipation, urinary retention, delirium, and cognitive slowing.510 |
| Monoamine Transporters (NET / SERT) | Transporter binding requires antidepressant blood levels (Tatsumi 1997; Owens 1997)46 | Negligible reuptake inhibition; zero antidepressant effect at 3 to 6 mg.23 | Active reuptake blockade: Drives mood effects and tricyclic drug interactions.46 |
Why the 2023 AGS Beers Criteria split doxepin at 6 mg/day: The American Geriatrics Society lists doxepin > 6 mg/day alongside amitriptyline and imipramine as a strong anticholinergic drug to avoid in adults 65 and older.10 By contrast, the 2023 Beers Criteria exempt doxepin <= 6 mg/day because its safety profile at 3 to 6 mg matches placebo in older-adult trials.10 That cutoff is not a razor-sharp wall. Slow CYP2C19 or CYP2D6 metabolizers, or patients who take doxepin right after a high-fat dinner, can still reach higher blood levels.2
What do sleep-lab trials show for low-dose doxepin (3 mg and 6 mg)?
Across five placebo-controlled trials (Roth 2007; Scharf 2008; Krystal 2010; Krystal 2011; Lankford 2012), doxepin 3 mg and 6 mg cut wake time after sleep onset (WASO) by 22 to 23 minutes and raised total sleep time (TST) by 26 to 32 minutes, with strong gains in the final hour of the night (AASM 2017).8911121314
In the American Academy of Sleep Medicine (AASM 2017) meta-analysis of sleep-lab (PSG) trials, both doses beat the clinical threshold for staying asleep:11
- Doxepin 3 mg vs. Placebo (AASM pooled PSG): Cut WASO by -22.17 minutes, raised TST by +26.14 minutes, and improved whole-night sleep efficiency by +6.78 percentage points.11
- Doxepin 6 mg vs. Placebo (AASM pooled PSG): Cut WASO by -23.14 minutes, raised TST by +32.27 minutes, and improved whole-night sleep efficiency by +7.06 percentage points.11
Why 3 mg and 6 mg perform almost the same on WASO: Raising the dose from 3 mg to 6 mg adds less than 1 minute of extra WASO reduction (-22.17 vs. -23.14 min) and about 6 minutes of total sleep. Meanwhile, it nudges next-day drowsiness up from 6% (3 mg) to 9% (6 mg), compared with 4% on placebo.211
| Pivotal Trial | Population & Design | Sleep Maintenance & Late-Night Findings | Next-Day Function, Tolerance & Withdrawal |
|---|---|---|---|
| Roth et al., Sleep 200712 | 67 adults (18-64 yr) with chronic insomnia; 4-period PSG crossover (1, 3, 6 mg vs placebo, 2 nights each) | 3 mg and 6 mg improved PSG WASO, TST, and sleep efficiency, including strong gains in the final third of the night (Hours 6-8).12 | Zero significant next-day psychomotor slowing (DSST, Symbol Copying) or memory/anticholinergic signal.12 |
| Scharf et al., J Clin Psychiatry 200813 | 76 older adults (>= 65 yr); 4-period PSG crossover (1, 3, 6 mg vs placebo) | Dose-related gains in WASO and TST; 3 mg and 6 mg improved sleep efficiency across all three thirds of the night.13 | Zero significant next-morning residual sedation or memory impairment detected.13 |
| Krystal et al., Sleep 20108 | 240 older adults (>= 65 yr); parallel 12-week PSG + outpatient RCT (1 mg or 3 mg vs placebo) | 3 mg cut WASO on Night 1 (-34 min vs placebo) and remained significant at Night 85 (Week 12), boosting final-quarter and Hour-8 sleep efficiency.8 | No tolerance over 12 weeks; next-day psychomotor scores at 1 mg and 3 mg matched placebo.28 |
| Krystal et al., Sleep 20119 | 221 adults (18-64 yr); 35-day PSG RCT (3 mg or 6 mg vs placebo) + 2 nights single-blind placebo withdrawal | 3 mg and 6 mg improved WASO at Nights 1, 15, and 29 and improved final-quarter efficiency (6 mg significant at all timepoints).9 | Zero rebound insomnia or withdrawal syndrome when switched abruptly to placebo on Nights 36-37.9 |
| Lankford et al., Sleep Med 201214 | 254 older adults (>= 65 yr); 4-week outpatient RCT (6 mg vs placebo; patient/clinician ratings, non-PSG) | Improved patient-reported TST and WASO through Week 4; no significant effect on sleep onset.14 | Overall adverse-event rate matched placebo; zero anticholinergic or memory signal.14 |
Three clinical nuances from the FDA label and trial data:
- Minimal effect on falling asleep (sleep onset): Histamine levels drop naturally at bedtime and surge toward dawn. Because doxepin blocks that early-morning histamine rise, it shines between 2:00 AM and 6:00 AM (final third/quarter of the night), while doing very little for someone who takes two hours to fall asleep at 11:00 PM.81114
- Residual sedation is uncommon, not zero (FDA Silenor Label): Across registration trials, next-day somnolence or sedation occurred in 4% on placebo, 6% on doxepin 3 mg, and 9% on doxepin 6 mg.2 While older adults taking 1 mg or 3 mg performed comparably to placebo on morning cognitive tests (Krystal 2010), the FDA label notes small decreases in Digit Symbol Substitution Test (DSST) and Symbol Copying Test scores in non-elderly adults taking 6 mg.28
- Why AASM graded the recommendation as conditional ("weak for"): The AASM 2017 guideline recommends doxepin 3 to 6 mg for sleep maintenance, grading it as conditional due to modest average effect sizes (~22-32 minutes), statistical imprecision across small trials, and potential industry publication bias.11
How does low-dose doxepin compare with hydroxyzine, Benadryl (diphenhydramine), and Unisom (doxylamine)?
Unlike hydroxyzine, diphenhydramine, and doxylamine, low-dose doxepin (3 to 6 mg) has replicated PSG sleep-maintenance efficacy over 12 weeks without tolerance, far less antimuscarinic burden, and an explicit exemption in the 2023 AGS Beers Criteria.28101115
Many patients and clinicians assume all antihistamine sleep aids work the same way. In reality, their receptor profiles, half-lives, and clinical trial records differ sharply:10151617
| Feature | Low-Dose Doxepin (3 to 6 mg / Silenor) | Hydroxyzine (25 to 50 mg / Atarax, Vistaril) | Diphenhydramine (25 to 50 mg / Benadryl, ZzzQuil) | Doxylamine (25 mg / Unisom SleepTabs) |
|---|---|---|---|---|
| FDA Insomnia Approval & AASM 2017 Ruling | FDA-approved (3 & 6 mg); AASM recommends FOR sleep maintenance.211 | Off-label; zero chronic-insomnia RCTs (5 small studies / 207 adults total, Burgazli 2023).15 | OTC; AASM recommends AGAINST for sleep onset and maintenance (effects below clinical threshold).11 | OTC; short-term network meta-analysis support (De Crescenzo 2022), no long-term insomnia RCTs.18 |
| Terminal Half-Life (t1/2) | ~15.3 hours (FDA Label)2 | 20.0 +/- 4.1 hr in adults, rising to 29.3 +/- 10.1 hr in older adults (Simons 1984/1989).1719 | 8 to 12 hours, extending up to 13.5+ hours in older adults.10 | ~10.1 hours in young adults, prolonged to ~12 to 15 hours in older men (Friedman 1985/1989).20 |
| Sedation Tolerance Over Time | No tolerance at 12 weeks (Night 85 in Krystal 2010).8 | Label notes drowsiness may fade after a few days; driving impairment persists at Day 8 (Conen 2011).2122 | Complete sedation tolerance by Day 4 (50 mg twice daily matched placebo on nap tests in Richardson 2002).16 | Tolerance and rebound poorly characterized in controlled long-term trials.18 |
| Next-Day Driving & Somnolence Data | Somnolence 6% (3 mg) to 9% (6 mg) vs 4% placebo; elderly 1-3 mg psychomotor scores matched placebo.28 | Nightly 50 mg raised daytime somnolence without sleep gain (Staevska 2014); impaired highway driving on Days 1 & 8 (Conen 2011).2223 | Acute 50 mg impaired driving simulator more than 0.10% alcohol (Weiler 2000); bedtime dosing caused next-day residual impairment (Kay 2016).2425 | Prolonged morning hangover due to ~10 to 15 hr elimination half-life.20 |
| Antimuscarinic & Cardiac (QTc) Risks | Negligible antimuscarinic load at <= 6 mg; 2023 Beers Criteria exempt <= 6 mg/day.10 | Lower antimuscarinic activity than diphenhydramine in vitro (Orzechowski 2005), yet 2023 Beers "Strong Avoid" + FDA/EMA QTc / torsades warnings.102126 | Strong antimuscarinic block; 2023 Beers Criteria "Strong Avoid" in age >= 65 (delirium, falls, urinary retention).10 | Strong antimuscarinic block; 2023 Beers Criteria "Strong Avoid" in age >= 65.10 |
Three key distinctions when comparing these options:
- Sedation tolerance (diphenhydramine vs. hydroxyzine vs. doxepin): The classic 4-day tolerance study (Richardson et al., J Clin Psychopharmacol 2002, n = 15) tested daytime diphenhydramine 50 mg twice daily. Objective and subjective sleepiness matched placebo by Day 4.16 For hydroxyzine, the FDA label notes subjective drowsiness may fade after a few days, yet a highway-driving trial (Conen et al., J Psychopharmacol 2011) proved hydroxyzine 50 mg still significantly impaired driving on both Day 1 and Day 8.2122 And in a randomized crossover trial (Staevska et al., Br J Dermatol 2014, n = 24), adding hydroxyzine 50 mg at bedtime increased daytime somnolence without improving sleep over a nonsedating antihistamine.23 By contrast, doxepin 3 mg maintained objective PSG sleep-maintenance gains through Night 85 (12 weeks) in Krystal et al. (2010).8
- Heart QTc safety (hydroxyzine vs. low-dose doxepin): Hydroxyzine carries US FDA contraindications in patients with a prolonged QT interval and European (EMA) dose caps (<= 100 mg/day in adults; avoid or <= 50 mg/day in older adults) due to torsades de pointes arrhythmia risk.2127 At 3 to 6 mg, doxepin showed zero clinically meaningful QTc prolongation in trials (even up to 50 mg in thorough QT testing per the FDA label).2
- Why generic 10 mg doxepin capsules are not a substitute for 3 to 6 mg: Standard generic doxepin capsules start at 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg. A 10 mg capsule is more than triple the 3 mg dose and crosses into the > 6 mg/day Beers Criteria "Avoid" zone.10 When 3 mg or 6 mg tablets are expensive on a plan, we prescribe doxepin 10 mg/mL oral concentrate (0.3 mL = 3 mg or 0.6 mL = 6 mg measured with an oral dropper) so you get the right low dose for pennies a night.
Evidence-Based Treatment
Dr. Ash reviews the research - and applies it to your specific biology.
Does low-dose doxepin carry the anticholinergic dementia risk seen with older sleep aids?
Large observational cohorts (Gray 2015; Richardson 2018; Coupland 2019) link multi-year exposure to strongly anticholinergic drugs with a 29% to 54% higher risk of dementia (HR 1.54 in Gray 2015; OR 1.49 in Coupland 2019). However, neither study evaluated doxepin at 3 to 6 mg, where antimuscarinic activity is minimal and Beers Criteria exempt its use.210282930
Understanding what the three landmark anticholinergic-dementia studies found - and what they did not test - helps avoid both false alarm and false complacency:282930
| Study | Design & Population | Main Dementia Finding | What It Means for Doxepin 3-6 mg vs. Antihistamines |
|---|---|---|---|
| Gray et al., JAMA Intern Med 2015 (Adult Changes in Thought)28 | Prospective cohort of 3,434 adults >= 65 yr tracked for 10 years (excluding the final year before diagnosis) | > 1,095 total standardized daily doses (TSDDs, > 3 years daily): dementia HR 1.54 (95% CI 1.21-1.96); Alzheimer's HR 1.63 (1.24-2.14).28 | Pooled tricyclics, 1st-gen antihistamines (diphenhydramine, chlorpheniramine), and bladder antimuscarinics. Cited doxepin 10 mg/day for > 3 years as an example of heavy tricyclic exposure - did not study 3 to 6 mg (Silenor).28 |
| Richardson et al., BMJ 2018 (UK CPRD)30 | Nested case-control of 40,770 dementia cases and 283,933 controls (4 to 20 years prior prescriptions) | Significant dose-response dementia risk for anticholinergic antidepressants (ACB 3, OR 1.24), urologicals (OR 1.23), and antiparkinson drugs.30 | Antihistamines (ACB 3) did not show a statistically significant dose-response association in prescription records (though OTC diphenhydramine was unmeasured).30 |
| Coupland et al., JAMA Intern Med 2019 (UK QResearch)29 | Nested case-control of 58,769 dementia cases and 225,574 controls (>= 55 yr) | Top exposure (> 1,095 TSDDs): overall dementia OR 1.49 (95% CI 1.44-1.54); anticholinergic antidepressants OR 1.29 (1.24-1.34).29 | Antihistamines were not significantly associated (OR 1.14, 95% CI 0.98-1.34); antidepressant signal reflected tricyclic dosing (>= 10-150 mg), not 3-6 mg insomnia dosing.29 |
Three takeaways on long-term brain safety:
- Why Gray 2015 mentioned doxepin 10 mg/day: In Gray et al. (2015), 10 mg/day of doxepin was the minimum daily dose threshold used to count a prescription as 1 standardized daily dose of a tricyclic antidepressant.28 That aggregate HR (1.54) does not apply to 3 to 6 mg doxepin, where muscarinic receptor occupancy (Kd 83 nM) is a tiny fraction of H1 occupancy (Kd 0.24 nM).1228
- Association is not proof of drug-specific causation (Cochrane 2021; Andrade 2019): Disturbed sleep, anxiety, and depression are early prodromal signs of Alzheimer's disease years before memory loss begins. Because of that, observational prescribing cohorts cannot rule out reverse causation (confounding by indication).293132
- Short-term safety does not prove 10-year safety: Controlled trials of doxepin 3 to 6 mg extend to 12 weeks (Krystal 2010), showing zero short-term memory decline.8 Because no 10-year dementia trial exists for 3 to 6 mg doxepin, we pair it with first-line CBT-I (Morin & Buysse, NEJM 2024) and re-evaluate after 8 to 12 weeks instead of refilling it indefinitely on autopilot.233
Guidance from the Clinic
Actionable Steps
How to use ultra-low-dose doxepin (3 to 6 mg) safely and effectively:
- Match the Medication to Your Sleep Pattern (3:00 AM Waking vs. Bedtime Onset): Use doxepin 3 to 6 mg when your core problem is waking in the second half of the night (WASO) or early morning (Roth 2007; Krystal 2010). If your main trouble is falling asleep at bedtime, start with CBT-I stimulus control.
- Audit the Milligram Strength on Your Bottle (3 to 6 mg Only): Start at 3 mg nightly in older adults (>= 65 yr) and 3 mg or 6 mg nightly in younger adults (maximum 6 mg/day).2 If your bottle says 10 mg or 25 mg capsules, ask your prescriber to switch to 3 mg tablets or doxepin 10 mg/mL oral solution (0.3 mL = 3 mg; 0.6 mL = 6 mg).
- Follow the 3-Hour Post-Meal Rule (FDA Label): Take doxepin within 30 minutes of bedtime and at least 3 hours after eating.2 Taking doxepin with a high-fat meal raises total absorption (AUC) by 41%, raises peak concentration (Cmax) by 15%, and delays peak blood levels by ~3 hours, increasing next-morning drowsiness.2
- Check Contraindications and CYP2C19 / CYP2D6 Interactions: Never take doxepin within 14 days of an MAOI, or if you have untreated narrow-angle glaucoma or severe urinary retention.2 Tell your doctor if you take cimetidine (which doubles doxepin exposure) or strong CYP2C19 / CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, omeprazole), which require staying at 3 mg or less.2
- Screen for Obstructive Sleep Apnea and Pair with CBT-I: Waking at 3:00 AM with a dry mouth or racing heart is often REM-related sleep apnea instead of primary insomnia. Rule out sleep apnea and build CBT-I habits so you can step off medication once your sleep consolidates.
Key Takeaways
- Dose defines the drug (3 to 6 mg vs. >= 10 mg): At 3 to 6 mg, doxepin acts as a selective histamine H1 antagonist (Kd 0.24 nM vs. muscarinic Kd 83 nM, Richelson 1984). The 2023 AGS Beers Criteria explicitly exempt doxepin <= 6 mg/day while listing > 6 mg/day as a strong anticholinergic to avoid.110
- Proven for staying asleep (AASM 2017; Krystal 2010/2011): Pooled PSG trials show WASO -22.2 to -23.1 minutes and TST +26.1 to +32.3 minutes, holding efficacy through Week 12 (Night 85) with zero rebound insomnia on discontinuation.8911
- Start at 3 mg and respect the 3-hour food rule: 3 mg gives nearly the full WASO benefit of 6 mg with less next-day drowsiness (6% vs. 9%). Take it at least 3 hours after dinner so food does not boost absorption (+41% AUC) or delay peak levels into the morning.211
- Check your bottle strength: If a generic prescription says 10 mg or 25 mg capsules, ask for 3 mg tablets or doxepin 10 mg/mL oral liquid (0.3 mL = 3 mg) and pair it with first-line CBT-I.233
Related at Fishtown Medicine
- CBT-I for insomnia
- Sleeping pills compared head-to-head
- Doxepin (3-6 mg) vs. hydroxyzine (25-50 mg) for sleep
- Hydroxyzine for sleep
- Trazodone for sleep
- Gabapentin for sleep (100-600 mg)
- Z-drugs for insomnia
- Is it insomnia or sleep apnea?
Scientific References
- Richelson E, Nelson A. "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro." The Journal of Pharmacology and Experimental Therapeutics. 1984;230(1):94-102. PubMed
- Food and Drug Administration. "Silenor (doxepin hydrochloride) Tablets Prescribing Information." Updated January 2022. DailyMed
- Weber J, Siddiqui MA, Wagstaff AJ, McCormack PL. "Low-dose doxepin: in the treatment of insomnia." CNS Drugs. 2010;24(8):713-720. PubMed
- Tatsumi M, Groshan K, Blakely RD, Richelson E. "Pharmacological profile of antidepressants and related compounds at human monoamine transporters." European Journal of Pharmacology. 1997;340(2-3):249-258. PubMed
- Food and Drug Administration. "Doxepin Hydrochloride Capsules and Oral Concentrate Prescribing Information." Updated July 2025. DailyMed
- Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. "Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites." The Journal of Pharmacology and Experimental Therapeutics. 1997;283(3):1305-1322. PubMed
- Stanton T, Bolden-Watson C, Cusack B, Richelson E. "Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics." Biochemical Pharmacology. 1993;45(11):2352-2354. PubMed
- Krystal AD, Durrence HH, Scharf M, et al. "Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia." Sleep. 2010;33(11):1553-1561. PubMed
- Krystal AD, Lankford A, Durrence HH, et al. "Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia." Sleep. 2011;34(10):1433-1442. PubMed
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults." Journal of the American Geriatrics Society. 2023;71(7):2052-2081. DOI
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline." Journal of Clinical Sleep Medicine. 2017;13(2):307-349. PMC
- Roth T, Rogowski R, Hull S, et al. "Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia." Sleep. 2007;30(11):1555-1561. PubMed
- Scharf M, Rogowski R, Hull S, et al. "Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study." The Journal of Clinical Psychiatry. 2008;69(10):1557-1564. PubMed
- Lankford A, Rogowski R, Essink B, et al. "Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia." Sleep Medicine. 2012;13(2):133-138. PubMed
- Burgazli CR, Rana KB, Brown JN, Tillman F. "Efficacy and safety of hydroxyzine for sleep in adults: Systematic review." Human Psychopharmacology. 2023;38(2):e2864. PubMed
- Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. "Tolerance to daytime sedative effects of H1 antihistamines." Journal of Clinical Psychopharmacology. 2002;22(5):511-515. PubMed
- Simons KJ, Watson WT, Chen XY, Simons FE. "Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly." Clinical Pharmacology and Therapeutics. 1989;45(1):9-14. PubMed
- De Crescenzo F, D'Alo GL, Ostinelli EG, et al. "Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis." The Lancet. 2022;400(10347):170-184. PubMed
- Simons FE, Simons KJ, Frith EM. "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." The Journal of Allergy and Clinical Immunology. 1984;73(1 Pt 1):69-75. PubMed
- Friedman H, Greenblatt DJ, Scavone JM, Burstein ES, Ochs HR, Harmatz JS, Shader RI. "Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women." Clinical Pharmacokinetics. 1989;16(5):312-316. PubMed
- Food and Drug Administration. "Hydroxyzine Hydrochloride Prescribing Information." Updated June 2026. DailyMed
- Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG. "Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers." Journal of Psychopharmacology. 2011;25(11):1517-1523. DOI
- Staevska M, Gugutkova M, Lazarova C, et al. "Night-time sedating H1-antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial." The British Journal of Dermatology. 2014;171(1):148-154. PubMed
- Weiler JM, Bloomfield JR, Woodworth GG, et al. "Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa Driving Simulator." Annals of Internal Medicine. 2000;132(5):354-363. PubMed
- Kay GG, Schwartz HI, Wingertzahn MA, Jayawardena S, Rosenberg RP. "Next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double-blind, placebo-controlled, crossover trial." Human Psychopharmacology. 2016;31(3):217-226. DOI
- Orzechowski RF, Currie DS, Valancius CA. "Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models." European Journal of Pharmacology. 2005;506(3):257-264. PubMed
- Morales DR, Macfarlane T, MacDonald TM, et al. "Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis." Pharmacoepidemiology and Drug Safety. 2021;30(4):477-485. DOI
- Gray SL, Anderson ML, Dublin S, et al. "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study." JAMA Internal Medicine. 2015;175(3):401-407. PubMed
- Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. "Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study." JAMA Internal Medicine. 2019;179(8):1084-1093. PubMed
- Richardson K, Fox C, Maidment I, et al. "Anticholinergic drugs and risk of dementia: case-control study." BMJ. 2018;361:k1315. PubMed
- Taylor-Rowan M, Edwards S, Noel-Storr AH, et al. "Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome." Cochrane Database of Systematic Reviews. 2021;5(5):CD013540. DOI
- Andrade C. "Anticholinergic drug exposure and the risk of dementia: there is modest evidence for an association but not for causality." The Journal of Clinical Psychiatry. 2019;80(4):19f13000. PubMed
- Morin CM, Buysse DJ. "Management of Insomnia." The New England Journal of Medicine. 2024;391(3):247-258. DOI
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.


